A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Trial Profile

A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Napabucasin (Primary) ; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Regorafenib
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 30 Jun 2017 Results from arms combining napabucasin with FOLFIRI with or without bevacizumab presented at the European Society of Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer, according to a Boston Biomedical media release.
    • 30 Jun 2017 Results from arms combining napabucasin with FOLFIRI with or without bevacizumab published in a Boston Biomedical media release.
    • 06 Jun 2017 Results (n=82) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top